189 related articles for article (PubMed ID: 35777135)
1. Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer.
Saigí M; Carcereny E; Morán T; Cucurull M; Domènech M; Hernandez A; Martinez-Cardús A; Pros E; Sanchez-Cespedes M
Cancer Treat Rev; 2022 Sep; 109():102430. PubMed ID: 35777135
[TBL] [Abstract][Full Text] [Related]
2. LTK fusions: A new target emerges in non-small cell lung cancer.
Cooper AJ; Sequist LV; Johnson TW; Lin JJ
Cancer Cell; 2022 Jan; 40(1):23-25. PubMed ID: 35016028
[TBL] [Abstract][Full Text] [Related]
3. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.
Zhu VW; Klempner SJ; Ou SI
Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287
[TBL] [Abstract][Full Text] [Related]
4. The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Izumi H; Matsumoto S; Liu J; Tanaka K; Mori S; Hayashi K; Kumagai S; Shibata Y; Hayashida T; Watanabe K; Fukuhara T; Ikeda T; Yoh K; Kato T; Nishino K; Nakamura A; Nakachi I; Kuyama S; Furuya N; Sakakibara-Konishi J; Okamoto I; Taima K; Ebi N; Daga H; Yamasaki A; Kodani M; Udagawa H; Kirita K; Zenke Y; Nosaki K; Sugiyama E; Sakai T; Nakai T; Ishii G; Niho S; Ohtsu A; Kobayashi SS; Goto K
Nature; 2021 Dec; 600(7888):319-323. PubMed ID: 34819663
[TBL] [Abstract][Full Text] [Related]
5. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
6. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
7. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
8. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
Xia H; Xue X; Ding H; Ou Q; Wu X; Nagasaka M; Shao YW; Hu X; Ou SI
Clin Lung Cancer; 2020 May; 21(3):247-254. PubMed ID: 31761448
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
10. Targeting SLMAP-ALK-a novel gene fusion in lung adenocarcinoma.
Pagan C; Barua S; Hsiao SJ; Mansukhani M; Saqi A; Murty V; Fernandes H
Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160357
[TBL] [Abstract][Full Text] [Related]
11. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
12. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
Halliday PR; Blakely CM; Bivona TG
Curr Oncol Rep; 2019 Feb; 21(3):21. PubMed ID: 30806814
[TBL] [Abstract][Full Text] [Related]
13. Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
Remon J; Ahn MJ; Girard N; Johnson M; Kim DW; Lopes G; Pillai RN; Solomon B; Villacampa G; Zhou Q
J Thorac Oncol; 2019 Jul; 14(7):1134-1155. PubMed ID: 31002952
[TBL] [Abstract][Full Text] [Related]
14. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
Velizheva NP; Rechsteiner MP; Valtcheva N; Freiberger SN; Wong CE; Vrugt B; Zhong Q; Wagner U; Moch H; Hillinger S; Schmitt-Opitz I; Soltermann A; Wild PJ; Tischler V
Pathol Res Pract; 2018 Apr; 214(4):572-578. PubMed ID: 29580750
[TBL] [Abstract][Full Text] [Related]
15. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract][Full Text] [Related]
16. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
Morris TA; Khoo C; Solomon BJ
Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
[TBL] [Abstract][Full Text] [Related]
17. EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature.
Copia Sperandio R; Luiza Teixeira Tostes F; Vidal Campregher P; Ribeiro Paes V; Moura F; Schvartsman G
Lung Cancer; 2022 Apr; 166():94-97. PubMed ID: 35245845
[TBL] [Abstract][Full Text] [Related]
18.
Ross JS; Ali SM; Fasan O; Block J; Pal S; Elvin JA; Schrock AB; Suh J; Nozad S; Kim S; Jeong Lee H; Sheehan CE; Jones DM; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Miller VA; Stephens PJ; Gay LM
Oncologist; 2017 Dec; 22(12):1444-1450. PubMed ID: 29079636
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
20. Oncogene addicted non-small-cell lung cancer: current standard and hot topics.
Vecchiarelli S; Bennati C
Future Oncol; 2018 Jun; 14(13s):3-17. PubMed ID: 29989448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]